论文部分内容阅读
尽管目前市场上有多种AIDS治疗药物,但由于逆转录病毒易出现耐药性,必须通过现有药物的更新换代来克服病毒耐药性带来的问题。目前一种新的小分子抗病毒药物maraviroc可以特异性拮抗化学因子CCR5受体,而CCR5受体是HIV感染的必经途径,因此它可以作为一种广谱抗HIV药物。前期临床试验结果表明,maraviroc具有良好的药代动力学和安全特性,因此在HIV的联合治疗中具有广阔前景。目前maraviroc已经进入Ⅲ期临床试验。
Despite the availability of multiple AIDS drugs on the market, retroviruses are susceptible to drug resistance problems that have to be overcome by the replacement of existing ones. At present, a new small molecule anti-viral drug, maraviroc, can specifically antagonize the chemical CCR5 receptor, which is a necessary pathway for HIV infection. Therefore, it can be used as a broad-spectrum anti-HIV drug. Pre-clinical trial results show that maraviroc has good pharmacokinetic and safety characteristics and therefore has broad prospects for the combination therapy of HIV. Currently maraviroc has entered Phase III clinical trials.